Results 21 to 30 of about 2,212 (184)

Rilonacept and Other Interleukin-1 Inhibitors in the Treatment of Recurrent Pericarditis.

open access: yesCardiology in Review, 2022
Pericarditis is the commonest form of pericardial disease. Unfortunately, despite optimal treatment, approximately 15-30% of patients with acute pericarditis have recurrence.
Aronow, Wilbert S   +12 more
core   +4 more sources

Pericarditis at the crossroads: Unlocking the next wave of therapies [PDF]

open access: yesInternational Journal of Cardiology: Heart & Vasculature
Pericarditis is an inflammation of the pericardial sac with different aetiologies. While often self-limited, up to 30 % of cases recur or become chronic, causing significant morbidity. Traditional treatments – nonsteroidal anti-inflammatory drugs (NSAIDs)
Massimo Imazio   +5 more
doaj   +2 more sources

Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap) [PDF]

open access: yesBiologics: Targets & Therapy, 2008
Leigh D Church1, Sinisa Savic2, Michael F McDermott21Department of Rheumatology, Division of Immunity, Infection and Inflammation, Institute for Biomedical Research, The University of Birmingham, Birmingham, UK; 2Section of Musculoskeletal Disease, Leeds
Leigh D Church   +2 more
doaj   +2 more sources

Rilonacept and canakinumab [PDF]

open access: yesBritish Journal of Clinical Pharmacology, 2011
Two new orphan medicines, rilonacept [1, 2] (Regeneron®) and canakinumab [3, 4] (Ilaris®), are indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS). CAPS occur in a group of rare, inherited, inflammatory diseases where patients have a mutation in the NLRP3 (nucleotide-binding domain, leucine-rich family, pyrin domain-containing-
Eline A, Dubois   +2 more
openaire   +2 more sources

Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis [PDF]

open access: yes, 2022
OBJECTIVE: Polypharmacy management of recurrent pericarditis (RP) often involves long-term therapies, often with negative effects. Slow tapering of oral therapies is often required to avoid recurrence.
Basil S Lewis   +45 more
core   +1 more source

Wirksamkeit und Sicherheit von Rilonacept in der Behandlung von Patientinnen und Patienten mit Kälteurtikaria [PDF]

open access: yes, 2022
Hintergrund und Zielsetzung Die Kälteurtikaria (KU) charakterisiert sich durch kälteinduzierte, juckende Quaddeln und wird gemäß der aktuellen Leitlinie mit nichtsedierenden Antihistaminika behandelt.
Spittler, Sebastian
core   +1 more source

Interleukin-1β inhibitors for the management of acute gout flares: a systematic literature review

open access: yesArthritis Research & Therapy, 2023
Objectives The objective of this systematic review was to assess the effects of interleukin-1β (IL-1β) inhibitors on gout flares. Methods Studies published between 2011 and 2022 that evaluated the effects of IL-1β inhibitors in adult patients ...
Naomi Schlesinger   +3 more
doaj   +1 more source

Interleukin-1 Blockade in Polygenic Autoinflammatory Disorders: Where Are We now?

open access: yesFrontiers in Pharmacology, 2021
Polygenic autoinflammatory diseases (AIDs), such as systemic juvenile idiopathic arthritis (sJIA), adult-onset Still's disease, Kawasaki disease, idiopathic recurrent pericarditis (IRP), Behçet’s Syndrome, Crystal-induced arthropatihes such as gout or ...
Hana Malcova   +7 more
doaj   +1 more source

Tuberculosis in children and adolescents with rheumatic diseases using biologic agents: an integrative review [PDF]

open access: yesRevista Paulista de Pediatria, 2023
Objective: To conduct a bibliographic review on tuberculosis (TB) disease in children and adolescents with rheumatic diseases, being managed with biologic therapy. Data source: An integrative review with a search in the U.S. National Library of Medicine
Lenita de Melo Lima   +5 more
doaj   +1 more source

P154 Rilonacept use in lupus pericarditis

open access: yesLupus Science and Medicine
Luigi Adamo   +2 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy